What happened with AEMD today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Aethlon Medical is a clinical-stage company focused on the Hemopurifier. The device filters blood outside the body, using a protein called lectin to capture enveloped viruses and extracellular vesicles—small particles associated with cancer progression and severe infectious disease. The company is testing it in an Australian trial involving patients with solid tumors; its treatment benefits remain investigational.
The company has no revenue and no current research grants or contracts. It raises money through share offerings and warrant exercises to support development and operations, and needs additional financing to continue its work.
If approved, the Hemopurifier would primarily be sold to medical institutions, which would bill insurers or other healthcare payors. That sales model depends on coverage and adequate reimbursement, not just regulatory approval. The device is not approved for commercial marketing or sale in any jurisdiction; commercialization first requires clinical evidence of safety and effectiveness and the relevant regulatory approvals.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Aethlon's results depend on Hemopurifier clinical outcomes, regulatory approvals and available cash—not current product sales—with ExThera Medical's blood filters among its named competitors.
Cytosorbents Corp. competes with AETHLON MEDICAL INC in blood purification outside the body for severe illness and organ transplantation, but its hospital cartridges remove substances such as inflammatory mediators rather than the viruses and extracellular vesicles targeted by Aethlon's investigational Hemopurifier. Watch uptake of its EU-approved CytoSorb and ECOS-300CY as a benchmark for hospital use in these overlapping applications.
SeaStar Medical Holding Corporation and AETHLON MEDICAL INC both depend on clinical validation and hospital adoption of devices that treat severe illness outside the body. Aethlon's Hemopurifier removes viruses and extracellular vesicles, while SeaStar's SCD modifies the immune response to treat inflammatory injury, so its clinical and hospital-adoption news concerns a different treatment approach, not the same filter.
AETHLON MEDICAL INC earningsThis company
Aethlon Medical has no product sales, so this report will show how much cash its clinical work and Hemopurifier manufacturing use, and whether new financing is replacing it.
Read cash used in operations alongside cash on hand and financing proceeds, then check the costs of the Australian oncology trial and Hemopurifier manufacturing. Slower cash use while the trial continues would show that existing funds are carrying development further; faster use or dependence on share sales to replenish cash would show greater funding pressure and potential dilution. The question is how much room the company has before it needs more capital.
Cytosorbents Corp. earningsCTSO
Cytosorbents' report will show whether hospitals are adopting its blood-purification cartridges, giving Aethlon Medical a read on hospital use of extracorporeal treatments for severe illness, though the devices target different substances.
Look for uptake of CytoSorb and ECOS-300CY and any corresponding revenue change; do not treat these as evidence of Hemopurifier trial results. Rising uptake would suggest hospitals are using extracorporeal blood-purification devices in some severe-illness settings, a limited positive signal for Aethlon Medical's hospital-adoption prospects. Stalled uptake would point to an adoption hurdle, although the devices target different substances and have different evidence. The takeaway is whether the shared hospital setting shows demand, not whether Hemopurifier is validated.
